Financial Performance - For the third quarter, adjusted diluted earnings per share increased by 3.6%, and for the first nine months, it grew by 5.9% [5][20] - Adjusted operating companies income (OCI) for the smokeable products segment grew by 0.7% to nearly $3 billion in the third quarter and by 2.5% to $8.4 billion for the first nine months [20] - Adjusted OCI margins expanded to 64.4% for both the third quarter and first nine months, representing margin growth of 1.3 percentage points and 2.7 percentage points, respectively [20] Business Segment Performance - Domestic cigarette volumes declined by 8.2% in the third quarter and 10.6% for the first nine months when adjusted for trade inventory movements and calendar differences [21][22] - Marlboro expanded its share of the premium segment by 0.3 to 59.6% in the third quarter, while the discount segment of the industry expanded by 2.4 share points year over year, with Basic capturing over half of that growth [22][23] - In the oral tobacco products segment, adjusted OCI declined by less than 1% in the third quarter, but adjusted OCI margin expanded by 2.4 percentage points to 69.2% for the first nine months [24][25] Market Data - The nicotine pouch category saw an estimated 14.5% increase in industry volume over the past six months, with ON's retail share of the total oral tobacco category at 8.7% for the third quarter [6][8] - The e-vapor category included approximately 21 million vapers at the end of the third quarter, up nearly 2 million from a year ago, with flavored disposable e-vapor products representing over 60% of the category [13][15] Company Strategy and Industry Competition - The company announced a collaboration with KT&G to explore opportunities in international innovative smoke-free products and non-nicotine products [5][18] - The FDA's pilot program to streamline PMTA reviews for oral nicotine pouches is seen as a positive development, with ON+ applications included in the program [16][17] Management Commentary on Operating Environment and Future Outlook - Management noted that consumers are under pressure but are seeing some consistency in gas prices and inflation, which may influence purchasing behavior [33] - The company raised the lower end of its 2025 guidance range, now expecting adjusted diluted EPS in the range of $5.37 to $5.45, representing a growth rate of 3.5% to 5% from a base of $5.19 in 2024 [26][27] Other Important Information - The company returned nearly $6 billion to shareholders in the first nine months, including $5.2 billion in dividends and $712 million in share repurchases [27] - The board authorized the expansion of the share repurchase program from $1 billion to $2 billion, which now expires on December 31, 2026 [27] Q&A Session Summary Question: Insights on fourth quarter earnings growth and smokeable OCI - Management acknowledged the impact of share repurchase and MSA legal fund expiration on earnings growth, emphasizing the need to monitor consumer spending in a dynamic marketplace [30][31] Question: Drivers behind moderation in cigarette industry decline - Management indicated that consistency in consumer pressures, such as gas prices and inflation, may be contributing to the moderation observed [32][33] Question: Performance and initiatives for the nicotine pouch category - Management expressed satisfaction with ON's performance despite competitive pressures and highlighted the importance of retail takeaway volume as a measure of consumer demand [36][38] Question: KT&G partnership and operational efficiencies - Management outlined three prongs of the partnership: expanding ON and ON+ internationally, exploring non-nicotine opportunities, and improving operational efficiencies [39][41] Question: ON+ pricing strategy and controllable costs - Management confirmed ON+ is positioned as a premium product and discussed the importance of long-term cost management strategies in the smokeable category [46][49]

Financial Data and Key Metrics Changes - Adjusted diluted earnings per share increased by 3.6% in Q3 and by 5.9% for the first nine months [20] - Adjusted operating companies income (OCI) for smokeable products grew by 0.7% to nearly $3 billion in Q3 and by 2.5% to $8.4 billion for the first nine months [20] - Adjusted OCI margins expanded to 64.4% for both Q3 and the first nine months, representing margin growth of 1.3 percentage points and 2.7 percentage points respectively [20] Business Line Data and Key Metrics Changes - Domestic cigarette volumes declined by 8.2% in Q3 and 10.6% for the first nine months when adjusted for trade inventory movements [21] - The oral tobacco products segment saw adjusted OCI decline by less than 1% in Q3, but adjusted OCI increased by 3.3% with margin expansion of 1.8 percentage points to 69% [24][25] - Helix's reported shipment volume for on! increased by nearly 1% in Q3 and approximately 15% for the first nine months [8] Market Data and Key Metrics Changes - The nicotine pouch category grew to 55.7 share points, an increase of 11.1 share points year-over-year [7] - The e-vapor category included approximately 21 million vapers, up nearly 2 million versus a year ago [13] - The discount segment of the industry expanded by 2.4 share points year-over-year, with Basic capturing over half of that growth [23] Company Strategy and Development Direction - The company is focusing on expanding its smoke-free portfolio and exploring international opportunities through a collaboration with KT&G [5][18] - The launch of on! PLUS is seen as a premium product aimed at appealing to both adults who dip and competitive nicotine pouch consumers [10] - The company is committed to returning value to shareholders, as evidenced by a recent dividend increase and an expansion of the share repurchase program [5][27] Management Comments on Operating Environment and Future Outlook - Management noted that consumers are under pressure but are seeing some consistency in gas prices and inflation [33] - The company is optimistic about the regulatory environment, particularly with recent FDA actions that may streamline product authorizations [16] - The company raised the lower end of its 2025 guidance range, expecting adjusted diluted EPS in the range of $5.37-$5.45, representing a growth rate of 3.5%-5% from a base of $5.19 in 2024 [26] Other Important Information - The company returned nearly $6 billion to shareholders in the first nine months, including $5.2 billion in dividends and $712 million in share repurchases [27] - The balance sheet remains strong, with a debt to EBITDA ratio of 2x as of September 30 [28] Q&A Session Summary Question: Insights on fourth quarter earnings growth and smokeable OCI - Management acknowledged the impact of share repurchase and MSA legal fund expiration on earnings growth, while monitoring consumer spending in a dynamic marketplace [31] Question: Drivers behind the moderation in cigarette industry decline - Management indicated that consistency in consumer pressures and stepped-up enforcement in e-vapor are influencing market dynamics [34] Question: Performance and positioning of on! in a competitive environment - Management expressed satisfaction with on!'s performance despite competitive pressures, highlighting steady retail takeaway volume [37] Question: Opportunities from the KT&G partnership - Management outlined three prongs of the partnership: expanding modern oral initiatives, exploring non-nicotine opportunities, and improving operational efficiencies [40] Question: Pricing strategy for on! PLUS - Management confirmed that on! PLUS is positioned as a premium product, with introductory price promotions planned for its launch [48] Question: Impact of FDA pilot program on product launches - Management emphasized the importance of a functioning regulatory system and indicated that decisions will be made in the long-term best interest of the company [57]

Financial Data and Key Metrics Changes - Adjusted diluted earnings per share increased by 3.6% in Q3 and by 5.9% for the first nine months [18] - Adjusted operating companies income (OCI) for smokeable products grew by 0.7% to nearly $3 billion in Q3 and by 2.5% to $8.4 billion for the first nine months [18] - Adjusted OCI margins expanded to 64.4% for both Q3 and the first nine months, representing margin growth of 1.3 percentage points and 2.7 percentage points respectively [18] Business Line Data and Key Metrics Changes - Domestic cigarette volumes declined by 8.2% in Q3 and 10.6% for the first nine months when adjusted for trade inventory movements [18] - Marlboro expanded its share of the premium segment by 0.3 to 59.6% in Q3 [19] - The oral tobacco products segment saw adjusted OCI decline by less than 1% in Q3, but adjusted OCI margin expanded by 2.4 percentage points to 69.2% for the first nine months [22] Market Data and Key Metrics Changes - The nicotine pouch category grew to 55.7 share points, an increase of 11.1 share points year over year [5] - The e-vapor category included approximately 21 million vapers, up nearly 2 million versus a year ago [11] - Retail share for oral tobacco products was 31.1% for Q3 and 32.9% for the first nine months [23] Company Strategy and Development Direction - The company is focusing on expanding its smoke-free portfolio and exploring international opportunities in innovative smoke-free products [4][15] - A collaboration with KT&G was announced to explore opportunities in international innovative smoke-free products and non-nicotine products [4][16] - The company aims to maintain profitability in the premium segment while also investing in the discount segment to capture price-sensitive consumers [20][21] Management's Comments on Operating Environment and Future Outlook - Management noted that consumer spending remains under pressure due to macroeconomic factors, but they are optimistic about maintaining profitability [30] - The company raised the lower end of its 2025 guidance range, expecting adjusted diluted EPS in the range of $5.37 to $5.45 [24] - Management emphasized the importance of a functioning regulatory system and the need for accelerated product authorizations from the FDA [14][54] Other Important Information - The company returned nearly $6 billion to shareholders, including $5.2 billion in dividends and $712 million in share repurchases [25] - The board authorized the expansion of the share repurchase program from $1 billion to $2 billion, which now expires on December 31, 2026 [25] Q&A Session Summary Question: Insights on fourth quarter earnings growth deceleration - Management acknowledged the impact of share repurchase and MSA legal fund expiration on earnings growth, while monitoring consumer spending [29][30] Question: Drivers behind the moderation in cigarette industry decline - Management indicated that consistency in gas prices and inflation may have contributed to the moderation in decline [31][32] Question: Performance and positioning of ON in the nicotine pouch category - Management expressed satisfaction with ON's performance despite competitive pressures and highlighted the importance of retail takeaway volume [33][34] Question: Opportunities from the KT&G partnership - Management discussed three pronged opportunities: expanding ON internationally, exploring non-nicotine products, and improving operational efficiencies [36][39] Question: Clarification on duty drawbacks and EPS growth - Management stated that duty drawbacks are an additional benefit but emphasized the need for a functioning regulatory system for long-term decisions [52][54] Question: Impact of FDA pilot program on ON+ launch - Management clarified that decisions will be based on long-term interests and the functioning of the regulatory system [53][54]

Core Viewpoint - Altria reported mixed Q3 financial results, beating earnings expectations but missing revenue targets [1] Financial Performance - The company exceeded earnings expectations, indicating strong profitability [1] - Revenue figures fell short of market expectations, suggesting potential challenges in sales growth [1]

Altria (MO) came out with quarterly earnings of $1.45 per share, beating the Zacks Consensus Estimate of $1.44 per share. This compares to earnings of $1.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +0.69%. A quarter ago, it was expected that this owner of Philip Morris USA, the nation's largest cigarette maker would post earnings of $1.37 per share when it actually produced earnings of $1.44, delivering a surprise of +5 ...

Financial Performance - Altria's adjusted diluted EPS increased by 3.6% from $1.40 in Q3 2024 to $1.45 in Q3 2025[8] - For the first nine months of 2025, Altria returned nearly $6 billion to shareholders, including $5.2 billion in dividends and $712 million in share repurchases[98] - Altria increased its quarterly dividend by 3.9% to $1.06 per share[19] - The company expanded its existing share repurchase program from $1 billion to $2 billion[19] - The company is raising the lower-end of its full-year 2025 guidance range and now expects to deliver adjusted diluted EPS in a range of $5.37 to $5.45, representing a growth rate of 3.5% to 5.0% from 2024[95] Oral Tobacco Category - The oral tobacco industry volume increased by 14.5% for the six months ended September 30, 2025[22] - Oral nicotine pouches retail share of the oral tobacco category increased by 11.1 percentage points from Q3 2024 to Q3 2025, reaching 55.7%[22] - on! reported shipment volume increased by 0.7% in Q3 2025, with 42.2 million cans shipped[25] - For the nine months ended September 30, 2025, on! reported shipment volume increased by 14.8% to 133.6 million cans[25] - on!'s share of the oral tobacco category increased by 0.8 percentage points to 8.7% for the nine months ended September 30, 2025[28] Regulatory and Enforcement - Horizon submitted a combined PMTA & MRTPA to the FDA[32] - The FDA launched a pilot program to streamline PMTA reviews for oral nicotine pouches, and applications for on! PLUS are included in the program[47, 49]

Core Insights - Altria's annual profit forecast is significantly below market expectations due to decreased demand for cigarettes and oral smoking alternatives like on! nicotine pouches [1] Company Summary - Altria is experiencing lower demand for its traditional cigarette products and newer oral smoking alternatives, which is impacting its profitability outlook [1] Industry Summary - The tobacco industry is facing challenges with declining demand for traditional smoking products, indicating a potential shift in consumer preferences towards healthier alternatives [1]

Financial Performance - Net revenues for the nine months ended September 30, 2025, were $17,433 million, a decrease of 3.4% from $18,044 million in the same period of 2024[15]. - Gross profit for the nine months ended September 30, 2025, was $10,911 million, compared to $10,763 million for the same period in 2024, reflecting a slight increase of 1.3%[15]. - Net earnings for the nine months ended September 30, 2025, were $5,830 million, down 29.1% from $8,225 million in the same period of 2024[15]. - Basic and diluted earnings per share for the nine months ended September 30, 2025, were $3.45, compared to $4.75 for the same period in 2024, representing a decrease of 27.7%[15]. - Operating income for the nine months ended September 30, 2025, was $8,248 million, slightly down from $8,359 million in 2024[87]. - Earnings before income taxes for the nine months ended September 30, 2025, were $7,876 million, a decline of 27.5% compared to $10,881 million in 2024[102]. - For the nine months ended September 30, 2025, reported net earnings decreased by 29.1% to $5.83 billion, and diluted EPS decreased by 27.4% to $3.45 compared to the same period in 2024[208]. - Adjusted net earnings for the same period increased by 3.6% to $6.97 billion, while adjusted diluted EPS rose by 5.9% to $4.12 compared to 2024[208]. Assets and Liabilities - Total current assets increased to $5,119 million as of September 30, 2025, from $4,513 million as of December 31, 2024, marking a growth of 13.4%[10]. - Total liabilities increased to $37,604 million as of September 30, 2025, compared to $37,365 million as of December 31, 2024, an increase of 0.6%[12]. - The carrying value of the company's total long-term debt was $25.7 billion as of September 30, 2025, compared to $24.9 billion at December 31, 2024[73]. - The current portion of long-term debt rose to $1,569 million as of September 30, 2025, from $1,527 million as of December 31, 2024, an increase of 2.8%[12]. - The total stockholders' equity (deficit) attributable to Altria was $(2,646) million as of September 30, 2025, compared to $(2,238) million as of December 31, 2024[12]. Cash Flow and Investments - Cash provided by operating activities for the nine months ended September 30, 2025, was $6,019 million, compared to $5,413 million in 2024, indicating an increase of about 11.2%[24]. - Total cash, cash equivalents, and restricted cash at the end of September 2025 amounted to $3,496 million, an increase from $3,158 million at the beginning of the period[27]. - The company repurchased $712 million worth of common stock in the nine months ended September 30, 2025, at an average price of $58.08 per share[37]. - The net cash used in investing activities for the nine months ended September 30, 2025, was $(139) million, compared to $2,238 million in 2024[26]. - The company experienced losses from investments in equity securities amounting to $(398) million for the nine months ended September 30, 2025[24]. Dividends and Shareholder Returns - Cash dividends declared were $3.10 per share for the nine months ended September 30, 2025, totaling $5,231 million[19]. - The company declared cash dividends of $1.06 per share in August 2025, up from $1.02 per share, marking a 3.9% increase[33]. Legal and Regulatory Matters - The company recorded pre-tax charges of $44 million for tobacco and health litigation for the nine months ended September 30, 2025[115]. - PM USA has paid approximately $1.1 billion in judgments and settlements since October 2004, with interest totaling approximately $246 million as of September 30, 2025[116]. - The number of individual smoking and health cases pending against the company increased to 181 as of October 27, 2025, from 167 a year earlier[119]. - In October 2025, a jury awarded $1 million in compensatory damages and $5.5 million in punitive damages against PM USA and R.J. Reynolds in the Perez-Trinidad case[125]. - PM USA is named as a defendant in seven class actions filed in Canadian provinces, with a global settlement amount of CAD $32.5 billion agreed upon by other tobacco manufacturers[141]. Market Trends and Consumer Behavior - The discount share of the cigarette category reached 32.2% in Q3 2025, an increase of 2.4 share points from Q3 2024, indicating a shift in consumer preferences[202]. - Estimated domestic cigarette industry volume declined by 8% in Q3 2025 compared to Q3 2024, with PM USA's domestic cigarette shipment volume declining by an estimated 9%[202]. - The U.S. nicotine pouch category grew to 55.7% of the U.S. oral tobacco category, an increase of 11.1 share points from Q3 2024[202]. - Inflationary pressures on discretionary income have constrained consumer spending, particularly affecting lower-income tobacco consumers[201]. - Flavored disposable e-vapor products represent over 60% of the e-vapor category, with regulatory actions being taken against illicit products[204]. Strategic Initiatives - The company expects to complete the design and detailed plans for the Optimize & Accelerate initiative by early 2026, aiming to enhance organizational efficiency[56]. - Total pre-tax charges for the Optimize & Accelerate initiative are estimated to be approximately $125 million, with $111 million incurred as of September 30, 2025[57].

Exhibit 99.1 ALTRIA REPORTS 2025 THIRD-QUARTER AND NINE-MONTHS RESULTS; ANNOUNCES EXPANDED SHARE REPURCHASE PROGRAM; NARROWS 2025 FULL-YEAR EARNINGS GUIDANCE RICHMOND, Va. - October 30, 2025 - Altria Group, Inc. (NYSE: MO) today reports our 2025 third-quarter and nine-months business results, announces the expansion of our existing share repurchase program and narrows our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Altria continued to build significant momentum in the third quart ...

Core Insights - Altria Group, Inc. and Philip Morris International Inc. are navigating a transforming tobacco market with distinct strategies, focusing on smoke-free alternatives and maintaining strong brand presence [1][2] Altria Group, Inc. - Altria's pricing power is a key factor in its financial resilience, with a 10% net price realization in smokeable products leading to a 4.2% increase in adjusted operating companies income (OCI) in Q2 2025 [6] - The oral tobacco segment, particularly the on! nicotine pouch brand, saw shipments rise 26.5% year over year, contributing to a 10.9% increase in adjusted OCI [7] - Adjusted earnings per share (EPS) increased 8.3% year over year to $1.44 in Q2 2025, with revenues net of excise taxes at $5.29 billion [8] - Marlboro maintains a 59.5% share in the premium category, showcasing Altria's strong market position and ability to adapt to a smoke-free future [10] Philip Morris International Inc. - Philip Morris's growth is driven by smoke-free products, which accounted for 41% of total net revenues and 42% of gross profit in Q3 2025 [11] - Shipments of IQOS, ZYN, and VEEV showed significant growth, with IQOS shipments up 15.5% to 41 billion units, maintaining a 76% global share in heated tobacco [12] - Adjusted operating income rose 12.4% to $4.7 billion, with adjusted EPS increasing 17.3% to $2.24, supported by strong performance in smoke-free products [13] - Despite a 3.2% decline in cigarette shipment volumes, Philip Morris managed a 4.3% increase in net revenues through pricing strategies [14] Market Performance - Altria's stock has gained 25.3% over the past year, outperforming Philip Morris's 13.1% increase and the broader S&P 500's 20.6% rise [21] - Altria is trading at a forward P/E ratio of 11.41, while Philip Morris's forward P/E ratio stands at 18.24 [20] Investment Outlook - Altria is positioned as a better investment for income-focused investors due to its attractive valuation, robust pricing power, and growing smoke-free momentum, while Philip Morris offers stronger global growth potential [22]